Dostarlimab, PACLitaxel and CARBOplatin Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Dostarlimab, PACLitaxel and CARBOplatin Therapy, 2026, version number 1, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8284/929_Dostarlimab_-_PACLi_CARBO_Regimen.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
The treatment of adults with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
HSE (1)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel